Takeda Pharmaceutical (TAK) Earnings Date & Reports
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4... Show more
TAK is expected to report earnings to fall 486.18% to 18 cents per share on July 30
Takeda Pharmaceutical (TAK) FY2025 Earnings Recap: Resilient Results Amid Vyvanse Challenges
Key Takeaways
- Takeda reported FY2025 revenue of JPY 4,505.7 billion, down 1.7% year-over-year at actual exchange rates (AER), in line with management guidance.
- Core operating profit (non-IFRS measure excluding one-time items) reached JPY 1,172.5 billion, down 0.9% at constant exchange rates (CER), supported by cost savings.
- Reported EPS surged 78.1% to JPY 122, while core EPS grew 3.1% at CER to JPY 517.
- Adjusted free cash flow (non-IFRS) was JPY 684.5 billion, meeting forecasts despite headwinds.
- Pipeline progress highlighted with upcoming launches like oveporexton and rusfertide in H2 2026.
- FY2026 guidance calls for core revenue low-single digit decline at CER, with core operating profit down 5-8%.
Earnings Context and Why It Matters
Takeda's FY2025 results, covering April 2025 to March 2026, come amid ongoing pressure from generics eroding Vyvanse sales, a former blockbuster for ADHD. Investors watched closely for resilience in growth and launch products like Entyvio and Takhzyro, which partially offset declines. This report matters as it validates Takeda's cost discipline and pipeline momentum in a tough pharma environment marked by patent cliffs and R&D costs. Strong cash generation supports dividends and investments, signaling stability for shareholders amid broader sector volatility.
Takeda delivered FY2025 results in line with its latest management guidance. Reported revenue fell 1.7% YoY at AER to JPY 4,505.7 billion (core revenue down 2.6% at CER), primarily due to Vyvanse loss of exclusivity (LOE), mitigated by growth products.
Core operating profit dipped 0.9% at CER to JPY 1,172.5 billion (margin 26.0%), protected by operating expense (OPEX) savings despite growth investments. Reported operating profit rose 19.3% to JPY 408.8 billion, aided by lower Vyvanse amortization and restructuring costs.
Net profit climbed 77.7% to JPY 191.8 billion, driving reported EPS to JPY 122 (up 78.1%). Core EPS increased 3.1% at CER to JPY 517. Operating cash flow was JPY 1,041.4 billion, with adjusted free cash flow at JPY 684.5 billion. U.S. GAAP EPS was approximately $0.28 for the quarter per some reports, beating consensus of -$0.08.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Following the May 13 release, TAK shares showed limited movement, trading around $16.50, reflecting a muted response typical of in-line results. Investors appreciated the guidance achievement and pipeline updates but tempered enthusiasm due to FY2026's projected core declines amid continued Vyvanse erosion. Sentiment remains balanced, with focus shifting to upcoming launches and cost execution.
Forward Outlook and Key Factors to Monitor
Takeda issued FY2026 guidance for core revenue at JPY 4,640.0 billion (low-single digit % decline at CER) and core operating profit at JPY 1,160.0 billion (5%-8% decline at CER), reflecting planned investments in launches and R&D. Reported EPS is forecast at JPY 104, with core EPS at JPY 472 (mid-teens decline at CER). Adjusted free cash flow guidance is JPY 650-750 billion, supporting a proposed dividend increase to JPY 204 per share.
Key to watch: Progress on high-potential assets like oveporexton (narcolepsy), rusfertide (polycythemia vera), and zasocitinib (psoriasis), with U.S. launches eyed for H2 2026 and filings in Japan/China. Growth from Entyvio, Takhzyro, and new products must counter remaining Vyvanse pressures.
Monitor OPEX discipline, margin trends (targeting core OP margin stability), and adjusted net debt/EBITDA (2.6x at FY2025 end). Broader factors include FX impacts (CER normalizes rates), regulatory approvals, and U.S./EU reimbursement dynamics. Upcoming Q1 FY2026 earnings in July will provide early read on trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a pharmaceutical products manufacturer
Industry PharmaceuticalsGeneric